Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.
Ovchinsky N, Aumar M, Baker A, Baumann U, Bufler P, Cananzi M, Czubkowski P, Durmaz Ö, Fischer R, Indolfi G, Karnsakul WW, Lacaille F, Lee WS, Maggiore G, Rosenthal P, Ruiz M, Sokal E, Sturm E, van der Woerd W, Verkade HJ, Wehrman A, Clemson C, Yu Q, Ni Q, Ruvido J, Manganaro S, Mattsson JP.
Ovchinsky N, et al. Among authors: wehrman a.
Lancet Gastroenterol Hepatol. 2024 Apr 23:S2468-1253(24)00074-8. doi: 10.1016/S2468-1253(24)00074-8. Online ahead of print.
Lancet Gastroenterol Hepatol. 2024.
PMID: 38670135
Free article.